<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430066</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571POLIVERA</org_study_id>
    <nct_id>NCT00430066</nct_id>
  </id_info>
  <brief_title>Effects of Imatinib Mesylate in Polycythemia Vera</brief_title>
  <official_title>Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single
      agent, in inducing a haematological response in Polycythemia Vera.

      The patients will be asked to have additional bone marrow and blood samples collected: these
      samples will be used to evaluate how the disease is responding to the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematocrit &lt;45% in men or &lt;42% in women at 1Â°evaluation within 6 months In case of complete
      or partial responsiveness, experimental treatment will be continued until 12 months In case
      of disease progression or treatment failure, experimental drug will be withdrawn and patient
      will be out of the study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Haematocrit to less than 45%.</measure>
    <time_frame>6-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in platelet count and spleen size</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of incidence phlebotomies.</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms improvement in patients.</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Imatinib Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>400 mg/die for 6 months</description>
    <arm_group_label>Imatinib Mesylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Polycythemia Vera requiring treatment with either phlebotomy or
             Hydroxyurea

          -  Age &gt;18 years

          -  Signed written informed consent form

        Exclusion Criteria:

          -  Pregnancy or breast-feeding

          -  Creatinine &gt;3 max NV

          -  Bilirubin &gt;3 max NV

          -  AST/ALT &gt;3 max NV

          -  Concomitant and severe psychiatric disorder

          -  Concomitant neoplastic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrica Morra, MD</last_name>
    <role>Study Director</role>
    <affiliation>Divisione di Ematologia - Ospedale Niguarda Ca' Granda</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

